Clinical Trials

Sponsor: National Cancer Institute

Sponsor Study ID: 17C0102 C

Study Title: Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Select Rare CNS Cancers

NCT Number: NCT03173950

Phase: II

Protocol Type: Treatment

Age Group: Adult

Disease Sites: Brain and Nervous System

Study Objectives: This study will test whether the immunotherapy drug nivolumab is an effective treatment for people with rare CNS tumors. The objective is to learn if stimulating the immune system using the drug nivolumab can shrink tumors in people with rare CNS (brain or spine) tumors or increase the time it takes for these tumors to grow or spread.

If you would like to contact a MUSC study team member to learn more information about this study, click HERE.